^
    3ms
    H-200-001: A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers (clinicaltrials.gov)
    P1/2, N=198, Completed, Hookipa Biotech GmbH | Active, not recruiting --> Completed | Trial completion date: Jun 2026 --> Jan 2025 | Trial primary completion date: Jun 2025 --> Jan 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • eseba-vec (HB-200) • HB-201
    9ms
    A Study of HB-202/HB-201 in People With Human Papilloma Virus 16-Positive Head and Neck Squamous Cell Cancer (HPV 16+ HNSCC) (clinicaltrials.gov)
    P1, N=10, Recruiting, Memorial Sloan Kettering Cancer Center | Phase classification: P2 --> P1
    Phase classification
    |
    eseba-vec (HB-200) • HB-201
    9ms
    A Study of HB-202/HB-201 in People With Human Papilloma Virus 16-Positive Head and Neck Squamous Cell Cancer (HPV 16+ HNSCC) (clinicaltrials.gov)
    P2, N=10, Recruiting, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Recruiting
    Enrollment open
    |
    eseba-vec (HB-200) • HB-201
    11ms
    A Study of HB-202/HB-201 in People With Human Papilloma Virus 16-Positive Head and Neck Squamous Cell Cancer (HPV 16+ HNSCC) (clinicaltrials.gov)
    P2, N=3, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting | N=51 --> 3
    Enrollment closed • Enrollment change
    |
    eseba-vec (HB-200) • HB-201
    12ms
    H-200-004: A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer (clinicaltrials.gov)
    P2/3, N=0, Withdrawn, Hookipa Biotech GmbH | N=450 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • Metastases
    |
    Keytruda (pembrolizumab) • eseba-vec (HB-200) • HB-201
    1year
    H-200-001: A Phase 1/2 Study in Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers (clinicaltrials.gov)
    P1/2, N=200, Active, not recruiting, Hookipa Biotech GmbH | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    Keytruda (pembrolizumab) • eseba-vec (HB-200) • HB-201
    over1year
    A Phase 2/3 Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer (clinicaltrials.gov)
    P2/3, N=450, Not yet recruiting, Hookipa Biotech GmbH
    New P2/3 trial • Metastases
    |
    Keytruda (pembrolizumab) • eseba-vec (HB-200) • HB-201
    over1year
    A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers (clinicaltrials.gov)
    P1/2, N=200, Recruiting, Hookipa Biotech GmbH | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Mar 2024 --> Jun 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    Keytruda (pembrolizumab) • eseba-vec (HB-200) • HB-201
    over1year
    A Study of HB-202/HB-201 in People With Human Papilloma Virus 16-Positive Head and Neck Squamous Cell Cancer (HPV 16+ HNSCC) (clinicaltrials.gov)
    P2, N=51, Recruiting, Memorial Sloan Kettering Cancer Center
    New P2 trial
    |
    eseba-vec (HB-200) • HB-201
    almost2years
    A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer (clinicaltrials.gov)
    P1, N=10, Terminated, Hookipa Biotech GmbH | N=27 --> 10 | Recruiting --> Terminated; Sponsor decision.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
    |
    HB-201
    almost2years
    A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers (clinicaltrials.gov)
    P1/2, N=200, Recruiting, Hookipa Biotech GmbH
    Trial completion date • Trial primary completion date • Metastases
    |
    Keytruda (pembrolizumab) • eseba-vec (HB-200) • HB-201
    2years
    Characterization of tumor specific CD8+ T cell responses in patients with recurrent/metastatic HPV16-positive head and neck cancer receiving HB-200 monotherapy as second or later line treatment in a phase 1 study (SITC 2023)
    HB-200 is comprised of an alternating sequence of two replicating attenuated arenavirus vectors derived from LCMV (HB-201) and Pichinde virus (HB-202), respectively, expressing the same non-oncogenic HPV16 E7E6 fusion protein. Conclusions HB-200 monotherapy induces promising HPV16+ tumor-specific T cell responses and tumor infiltration in heavily pre-treated patients. This immune response coupled with clinical benefit in monotherapy suggests that HB-200 may enhance and strengthen current immunotherapy approaches by targeting specific tumor antigens.
    Clinical • P1 data • Metastases
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma)
    |
    eseba-vec (HB-200) • HB-201